These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1894 related articles for article (PubMed ID: 19093129)

  • 1. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort.
    Lenhard MS; Mitterer S; Kümper C; Stieber P; Mayr D; Ditsch N; Friese K; Burges A
    Eur J Obstet Gynecol Reprod Biol; 2009 Aug; 145(2):189-94. PubMed ID: 19477060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
    Panprom P; Lertkhachonsuk R
    J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors predicting recurrence in borderline ovarian tumors.
    Wu TI; Lee CL; Wu MY; Hsueh S; Huang KG; Yeh CJ; Lai CH
    Gynecol Oncol; 2009 Aug; 114(2):237-41. PubMed ID: 19481786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for recurrence and survival in primary vulvar squamous cell cancer.
    Ayhan A; Velipasaoglu M; Salman MC; Guven S; Gultekin M; Bayraktar O
    Acta Obstet Gynecol Scand; 2008; 87(11):1143-9. PubMed ID: 18949585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging.
    Rubin SC; Wong GY; Curtin JP; Barakat RR; Hakes TB; Hoskins WJ
    Obstet Gynecol; 1993 Jul; 82(1):143-7. PubMed ID: 8515915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.
    Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG
    Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.
    Sainz de la Cuesta R; Goff BA; Fuller AF; Nikrui N; Eichhorn JH; Rice LW
    Obstet Gynecol; 1994 Jul; 84(1):1-7. PubMed ID: 8008300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for stage I ovarian carcinoma.
    Seidman JD; Yemelyanova AV; Khedmati F; Bidus MA; Dainty L; Boice CR; Cosin JA
    Int J Gynecol Pathol; 2010 Jan; 29(1):1-7. PubMed ID: 19952945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
    Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
    J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.